-
公开(公告)号:US20180215827A1
公开(公告)日:2018-08-02
申请号:US15832337
申请日:2017-12-05
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20180022816A1
公开(公告)日:2018-01-25
申请号:US15627921
申请日:2017-06-20
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Edward N. VAN DEN BRINK , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD, D.M.Sc. , David SATIJN , Jan VAN DE WINKEL , Paul PARREN
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20220169738A1
公开(公告)日:2022-06-02
申请号:US17369542
申请日:2021-07-07
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20210122830A1
公开(公告)日:2021-04-29
申请号:US17003442
申请日:2020-08-26
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Edward N. VAN DEN BRINK , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD, D.M.Sc. , David SATIJN , Jan VAN DE WINKEL , Paul PARREN
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20180194845A1
公开(公告)日:2018-07-12
申请号:US15832366
申请日:2017-12-05
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20180179286A1
公开(公告)日:2018-06-28
申请号:US15832421
申请日:2017-12-05
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
-
-
-
-